Amyl Therapeutics is a preclinical stage biotechnology company.
Amyl Therapeutics has raised $6.5M in total funding. The most recent round was Grant. The last funding was announced in November 2023.
Amyl Therapeutics's investors include Mérieux Equity Partners, Sambrinvest, Smedvig, Meusinvest (Noshaq), Evren Ucok.
Amyl Therapeutics is headquartered in Liège, Belgium.
Amyl Therapeutics is a preclinical stage biotechnology company.
Amyl Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amyl Therapeutics — Funding & Investors." VCBacked, November 7, 2023, https://www.vcbacked.co/company/amyl-therapeutics. Accessed August 17, 2026.
VCBacked. (2023). Amyl Therapeutics — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/amyl-therapeutics
{{cite web |title=Amyl Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amyl-therapeutics |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated